Alamar Biosciences Posts 82% Revenue Growth and First 60% Gross Margin in Public Market Debut, Flags eMTBR-Tau and Immune 340 Launches as Next Growth Levers
Q2 2026 earnings call, August 10, 2026 — first quarterly report since April IPO
Alamar Biosciences used its inaugural earnings call as a public company to lay out a proteomics growth story that, on the numbers, is difficult to argue with. Total revenue reached $29.4 million in the second quarter, up 82% year-over-year from $16.2 million, while gross margin hit 60% for the first time in company history, up from 53% a year earlier. CEO Yuling Luo called it "a strong quarter that reflects the momentum of our business," and the underlying mix supports that framing: consumables revenue, the recurring piece of the model that matters most to long-term investors, grew 147% year-over-year to $15.5 million and now represents 53% of total revenue.
Consumables Pull-Through Is the Real Story
The most consequential data point for modeling purposes may be management's disclosure of the theoretical ceiling on per-instrument consumables pull-through. CFO Justin McAnear told analysts that running an ARGO HT instrument at full capacity — three plates per 24-hour period, five days a week — implies a ceiling of $5 million to $6 million in annual pull-through per instrument. Against that backdrop, the company's stated 2026 target of maintaining pull-through above $400,000 per instrument looks conservative, and management was explicit that the real constraint isn't platform capacity but customer behavior. As Luo explained, "many pharmas' time to result is critical to them. So they are not fully utilizing their capacity of the instrument, rather, they would rather buy a few more instruments to get the results faster." That is a notable disclosure because it suggests biopharma customers are effectively over-buying hardware relative to utilization, which should support instrument revenue even as consumables pull-through per box normalizes lower with a growing installed base — Justin McAnear noted new placements "will put some pressure on pull-through in the near term" simply due to ramp time on new accounts.
TAP Revenue Beat Expectations, But Management Downplays Durability
Service and other revenue, largely composed of the company's Technology Access Program (TAP), grew 49% to $6.2 million, driven by what McAnear called larger custom assay development projects — "significantly above what we have anticipated." Investors should treat this as a leading indicator rather than a recurring base: management was clear that TAP is not intended to be a long-term service business, with the explicit goal of converting TAP customers into instrument owners or CRO referrals. McAnear guided that the elevated TAP volume would continue into the third quarter "but not at the level that we saw in Q2," and expects TAP to grow slower than the rest of the business going forward as the platform's publication base expands and awareness reduces the need for hand-holding.
Clinical Diagnostics Ambition: The "iPhone" Analogy
Perhaps the most strategically important disclosure was the company's articulation of its path from a research-use-only tool into clinical diagnostics — a multi-billion-dollar expansion of total addressable market beyond the $9 billion research-proteomics opportunity management already sizes over the next decade. Luo framed the company's positioning bluntly: "Think of our platform as the iPhone. We provide the hardware and the operating system, and we enable third parties to build the applications." The plan involves developing a clinical-grade instrument, the ARGO HT/DX, and pursuing FDA marketing authorization first, with submission targeted for 2027, followed by partnerships with IVD and LDT companies to build differentiated diagnostic tests atop the platform. This is a capital-light strategy that offloads clinical development, regulatory, reimbursement and commercialization risk to partners — a sensible approach for a company still burning cash, but one that pushes any diagnostics-driven revenue meaningfully out on the timeline.
Neurology Franchise Momentum: eMTBR-Tau and the Gates Ventures Expansion
Alamar's core commercial engine remains its neurodegenerative disease franchise, and the quarter brought two developments that reinforce the company's positioning there. First, the July launch of eMTBR-tau — described as "the first commercial multiplex blood-based immunoassay" for a biomarker Luo said "is emerging as one of the most important biomarkers in Alzheimer's disease research" — lands at a moment when Biogen is advancing a tau-lowering drug into Phase III, a tailwind for demand. Management noted the platform's presence at the Alzheimer's Association International Conference (AAIC) grew to more than 140 posters and presentations featuring its NULISA technology, a fourfold increase year-over-year, which the company reads as validation that "blood-based biomarkers are going mainstream."
Second, Alamar disclosed an expansion of its strategic partnership with the Alzheimer's Disease Data Initiative and Gates Ventures, adding profiling of an additional 86,000 plasma samples and bringing the combined dataset under this initiative to more than 140,000 samples by 2027. Analysts pressed for clarity on cadence: President Tod White confirmed that a 21,000-sample national initiative (referred to as CLARiTI) is a subpart of the broader Gates Ventures/ADDI program, and that 2026 volumes are already contemplated in guidance, with the remainder phasing into the first half of 2027. These large cohort deals carry long lead times tied to sample logistics and institutional coordination, and management flagged that two outsized cohort orders drove an unusually large Q3-to-Q4 sequential step-up in 2025 — a pattern investors should not mechanically extrapolate this year, since McAnear noted current large-cohort revenue is "spread out over many quarters" rather than concentrated in a single quarter.
New Immune 340 Panel Extends the Playbook Beyond Neurology
Beyond neurology, Alamar launched its NULISAseq Immune 340 Panel two weeks before the call, expanding multiplex measurement to roughly 340 immune-related proteins from a single blood sample at attomolar sensitivity. Management frames chronic low-grade inflammation — implicated across cancer, cardiovascular, metabolic, neurological and autoimmune disease — as a second beachhead where Alamar can replicate its neurology success. It is early: Luo said the company is seeing only "early signs of adoption," and it will take several quarters of data to judge whether Immune 340 attach rates mirror the Neuro 220 ramp.
Guidance and Margin Trajectory
For the full year, Alamar guided to revenue of $116 million to $120 million, implying 59% growth at the midpoint — a deceleration from the 82% pace posted in the quarter, though third-quarter revenue is expected to step up only modestly, which McAnear defined explicitly as "low single-digit sequential growth from Q2 to Q3." On margins, McAnear cautioned against extrapolating the 60% print, guiding to "mid- to high 50s in the near term" before resuming an upward trajectory as consumables mix and manufacturing scale continue to build. Operating expenses nearly doubled year-over-year to $31.2 million, with SG&A up 129% to $17.4 million on public-company costs and personnel, while R&D rose 55% to $13.8 million. Net loss widened to $13.2 million from $7 million a year ago, though the company ended the quarter with $256.3 million in cash and short-term investments following its April IPO, which generated $197.8 million in net proceeds, and it separately refinanced its debt facility with SVB First Citizens Bank into a $100 million revolving credit line, expanding financial flexibility as it funds commercial, manufacturing and R&D expansion.
Instrument Placements Skew New, Not Just Expansion
On the demand-composition question analysts have flagged since the IPO, McAnear confirmed that the majority of instrument placements year-to-date have gone to new customers rather than expansion within the existing base, though Luo noted encouraging signs of multi-site expansion among existing accounts, calling it "a good indication of existing customers have found a lot of value and the utility of our platform." Management reiterated its 2026 target of adding at least 100 instruments to the installed base, a metric it will now disclose only annually rather than quarterly — a reporting change worth watching, since it reduces near-term visibility into unit economics for investors modeling the recurring consumables ramp.